Provided by Tiger Trade Technology Pte. Ltd.

Tiziana Life Sciences PLC

0.7701
-0.0819-9.61%
Post-market: 0.77600.0059+0.77%18:07 EDT
Volume:844.51K
Turnover:684.69K
Market Cap:97.80M
PE:-4.94
High:0.8800
Open:0.8482
Low:0.7615
Close:0.8520
52wk High:2.35
52wk Low:0.7615
Shares:127.00M
Float Shares:64.88M
Volume Ratio:2.17
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1558
EPS(LYR):-0.1558
ROE:-924.32%
ROA:-115.96%
PB:1880.82
PE(LYR):-4.94

Loading ...

Tiziana Life Sciences Initiated at Buy by BTIG

Dow Jones
·
Sep 03

Tiziana Life Sciences Ltd : Btig Initiates Coverage with Buy Rating; Price Target $7

THOMSON REUTERS
·
Sep 03

Tiziana Life Sciences Launches Phase 2a Banyan Trial of Intranasal Foralumab in ALS

Reuters
·
Aug 24

Tiziana Life Sciences Announces Poster Presentation on Phase 2a Banyan Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

THOMSON REUTERS
·
Aug 24

Tiziana Life Sciences CEO Elrifi Buys USD 321,423 in Shares

Reuters
·
Aug 06

Press Release: Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Dow Jones
·
Aug 06

Tiziana CEO Ivor Elrifi Acquires 667,000 Common Shares for $667,000

Reuters
·
Aug 06

Tiziana Life Sciences CEO Ivor Elrifi Lifts Stake to 4,472,261 Shares After Buying 667,000 at $1 Apiece

Reuters
·
Aug 04

Press Release: Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Dow Jones
·
Aug 04

Tiziana Reports up to 34% Drop in Brain Inflammation in Third MSA Patient on Intranasal Foralumab in Phase 2 Trial

Reuters
·
Jul 31

Tiziana Life Sciences - Third MSA Patient Shows up to 34% Reduction in SUV and 26% in Suvr in Brain Regions

THOMSON REUTERS
·
Jul 31

Tiziana Life Sciences - to Continue Evaluating Intranasal Foralumab in Additional MSA Patients

THOMSON REUTERS
·
Jul 31

Tiziana Life Sciences CEO Ivor Elrifi Files Initial Beneficial Ownership Statement

Reuters
·
Jul 24

Tiziana Life Sciences Chairman Cerrone Raises Stake to 34.93% After Buying 42,357 Shares at $0.99

Reuters
·
Jul 22

Tiziana Life Sciences Completes First Dosing in Phase 2 Inform-ms Trial of Intranasal Foralumab in Secondary Progressive MS

Reuters
·
Jun 25

Tiziana Announces Last Patient Successfully Dosed in Its Phase 2 Inform-ms Trial

THOMSON REUTERS
·
Jun 25

Tiziana Life Sciences - Topline Data from Inform-ms Trial Expected Late Q3 or Early Q4 2026

THOMSON REUTERS
·
Jun 25

Tiziana Life Sciences Executive Chairman Gabriele Cerrone Increases Holdings

MT Newswires Live
·
Jun 15

Tiziana Life Sciences’ COO and CFO Keeren Shah files initial beneficial ownership statement

Reuters
·
May 23

Tiziana Life Sciences Completes Patient Enrollment for Phase 2a Multiple Sclerosis Trial

MT Newswires Live
·
May 21